SG10201505723UA - Methods for detecting signatures of disease or conditions in bodily fluids - Google Patents

Methods for detecting signatures of disease or conditions in bodily fluids

Info

Publication number
SG10201505723UA
SG10201505723UA SG10201505723UA SG10201505723UA SG10201505723UA SG 10201505723U A SG10201505723U A SG 10201505723UA SG 10201505723U A SG10201505723U A SG 10201505723UA SG 10201505723U A SG10201505723U A SG 10201505723UA SG 10201505723U A SG10201505723U A SG 10201505723UA
Authority
SG
Singapore
Prior art keywords
disease
conditions
methods
bodily fluids
detecting signatures
Prior art date
Application number
SG10201505723UA
Inventor
I Kassis Amin
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of SG10201505723UA publication Critical patent/SG10201505723UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
SG10201505723UA 2010-07-23 2011-07-22 Methods for detecting signatures of disease or conditions in bodily fluids SG10201505723UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36700610P 2010-07-23 2010-07-23

Publications (1)

Publication Number Publication Date
SG10201505723UA true SG10201505723UA (en) 2015-09-29

Family

ID=45497477

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201505723UA SG10201505723UA (en) 2010-07-23 2011-07-22 Methods for detecting signatures of disease or conditions in bodily fluids
SG2013004791A SG187159A1 (en) 2010-07-23 2011-07-22 Methods for detecting signatures of disease or conditions in bodily fluids

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013004791A SG187159A1 (en) 2010-07-23 2011-07-22 Methods for detecting signatures of disease or conditions in bodily fluids

Country Status (12)

Country Link
US (5) US20120053073A1 (en)
EP (2) EP2596132A4 (en)
JP (5) JP2013538565A (en)
KR (1) KR20130041961A (en)
CN (2) CN110846405A (en)
AU (2) AU2011280996B2 (en)
BR (1) BR112013001754A2 (en)
CA (1) CA2806291C (en)
EA (1) EA201390150A1 (en)
MX (1) MX361944B (en)
SG (2) SG10201505723UA (en)
WO (1) WO2012012693A2 (en)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201704689XA (en) 2008-01-18 2017-07-28 Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
AU2011280936A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
EP2596116A4 (en) 2010-07-23 2014-03-19 Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
KR101212714B1 (en) * 2011-01-26 2013-01-22 계명대학교 산학협력단 Clinical diagnosis support method based on hierarchical fuzzy inference technology, and system
SG11201505515XA (en) 2012-01-27 2015-09-29 Univ Leland Stanford Junior Methods for profiling and quantitating cell-free rna
US9220733B2 (en) 2012-03-19 2015-12-29 The Regents Of The University Of California Solubilization of antigen components for removal from tissues
WO2013162458A1 (en) * 2012-04-24 2013-10-31 Wahren Herlenius Marie Ro52 AS A PREDICTIVE MARKER FOR IMMUNE DERIVED TUMOR OUTCOME
WO2013173642A1 (en) * 2012-05-18 2013-11-21 Sanford-Burnham Medical Research Institute High-throughput lipidomics
AU2013274002A1 (en) * 2012-06-15 2015-02-05 Harry Stylli Methods of detecting diseases or conditions
US20150141260A1 (en) * 2012-06-15 2015-05-21 Harry Stylli Methods of detecting diseases or conditions using circulating diseased cells
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
EP4036247B1 (en) 2012-09-04 2024-04-10 Guardant Health, Inc. Methods to detect rare mutations and copy number variation
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
NZ717423A (en) * 2012-09-20 2017-08-25 Univ Hong Kong Chinese Non-invasive determination of methylome of fetus or tumor from plasma
US10706957B2 (en) 2012-09-20 2020-07-07 The Chinese University Of Hong Kong Non-invasive determination of methylome of tumor from plasma
US9732390B2 (en) 2012-09-20 2017-08-15 The Chinese University Of Hong Kong Non-invasive determination of methylome of fetus or tumor from plasma
CA2887058C (en) * 2012-10-03 2022-02-22 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
CN102912029A (en) * 2012-11-06 2013-02-06 俞杨 Method for detecting single nucleotide polymorphism at site CISH+1320 of human tubercle bacillus related susceptibility gene
GB201220573D0 (en) 2012-11-15 2013-01-02 Univ Central Lancashire Methods of diagnosing proliferative disorders
GB201302837D0 (en) * 2013-02-19 2013-04-03 Univ Singapore Therapeutic Agents
EP2965077B1 (en) 2013-03-09 2022-07-13 Harry Stylli Methods of detecting cancer
EP3385717A3 (en) 2013-03-09 2018-10-24 Harry Stylli Methods of detecting prostate cancer
CA2902916C (en) 2013-03-14 2018-08-28 Mayo Foundation For Medical Education And Research Detecting neoplasm
US10119978B2 (en) * 2013-03-15 2018-11-06 Wallac Oy System and method for determining risk of diabetes based on biochemical marker analysis
CN107941681B (en) * 2013-04-19 2021-07-30 艾皮恩蒂斯有限公司 Method for identifying quantitative cellular composition in biological sample
CN103293321B (en) * 2013-05-27 2015-05-13 北京大学 Kit for detecting DNA (Deoxyribose Nucleic Acid) damage induced early-stage nucleolus stress and application of kit
CN103555818A (en) * 2013-07-16 2014-02-05 中国人民解放军海军医学研究所 Application of B cell translocation gene 2 as low dose ionizing radiation biological dosimeter
KR102099813B1 (en) * 2013-07-24 2020-04-10 더 차이니즈 유니버시티 오브 홍콩 Biomarkers for premature birth
CN104374853A (en) * 2013-08-14 2015-02-25 柯跃斌 Method for high performance liquid chromatography(HPLC)-mass spectrometry (MS) detection of DNA oxidation and DNA methylation
WO2015081110A2 (en) * 2013-11-27 2015-06-04 William Beaumont Hospital Method for predicting congenital heart defect
WO2015095359A1 (en) * 2013-12-17 2015-06-25 Harry Stylli Methods of detecting diseases or conditions
ES2660989T3 (en) 2013-12-28 2018-03-27 Guardant Health, Inc. Methods and systems to detect genetic variants
WO2015108663A1 (en) * 2014-01-16 2015-07-23 Illumina, Inc. Amplicon preparation and sequencing on solid supports
CN106062215B (en) * 2014-02-28 2020-09-22 国立研究开发法人国立癌研究中心 Method for determining prognosis of renal cell carcinoma
EP3126529B1 (en) 2014-03-31 2020-05-27 Mayo Foundation for Medical Education and Research Detecting colorectal neoplasm
EP2942400A1 (en) 2014-05-09 2015-11-11 Lifecodexx AG Multiplex detection of DNA that originates from a specific cell-type
RU2016147914A (en) 2014-05-09 2018-06-18 Лайфкодекс Аг DETECTION OF DNA THAT COMES FROM A SPECIFIC CELL TYPE AND RELATED TO IT
WO2015176066A2 (en) * 2014-05-16 2015-11-19 Intermune, Inc. Lpa-associated protein and rna expression
CN104101715A (en) * 2014-07-15 2014-10-15 重庆医科大学附属儿童医院 Kit for detecting DOCK8 (dedicator of cytokinesis 8) protein and non-diagnostic DOCK8 protein detection method
EP3191846A4 (en) 2014-09-11 2018-06-13 Harry Stylli Methods of detecting prostate cancer
CN104357559A (en) * 2014-10-27 2015-02-18 同济大学 Identification method for key ribosomal proteins in developmental regulation of female schistosoma japonicum katsurada
CN104280478B (en) * 2014-11-03 2016-03-30 天津中医药大学 Endogenous small-molecule substance is detecting the application in renal toxicity fast
CN107002132A (en) 2014-11-14 2017-08-01 液体基因有限公司 Circulate the purposes that acellular RNA is used to diagnosing and/or monitoring cancer
WO2016095093A1 (en) * 2014-12-15 2016-06-23 天津华大基因科技有限公司 Method for screening tumor, method and device for detecting variation of target region
US10030272B2 (en) 2015-02-27 2018-07-24 Mayo Foundation For Medical Education And Research Detecting gastrointestinal neoplasms
EP3316159A4 (en) 2015-06-25 2019-08-14 Advanced Telecommunications Research Institute International Prediction device based on multiple organ-related system and prediction program
CA2992790A1 (en) 2015-08-31 2017-03-09 Mayo Foundation For Medical Education And Research Detecting gastric neoplasm
JP6960924B2 (en) * 2015-09-17 2021-11-05 コンセホ・スペリオル・デ・インベスティガシオネス・シエンティフィカス(セエセイセ)Consejo Superior De Investigaciones Cientificas(Csic) Methods for detecting circulating cells in superficial body fluids
US20170097355A1 (en) * 2015-10-06 2017-04-06 University Of Washington Biomarkers and methods to distinguish ovarian cancer from benign tumors
DK3168309T3 (en) 2015-11-10 2020-06-22 Eurofins Lifecodexx Gmbh DETECTION OF Fetal Chromosomal Aneuploidies Using DNA Regions With Different Methylation Between Foster And The Pregnant Female
EP3387446A2 (en) * 2015-12-07 2018-10-17 Zora Biosciences OY Use of ceramides and lpls in diagnosing cvd
EP3390668A4 (en) 2015-12-17 2020-04-01 Guardant Health, Inc. Methods to determine tumor gene copy number by analysis of cell-free dna
CN105506083B (en) * 2015-12-24 2018-10-19 孙梅芬 CAPG is preparing the purposes in diagnosing parkinsonism product
CN205301177U (en) * 2015-12-31 2016-06-08 深圳市贝沃德克生物技术研究院有限公司 Domestic pneumonia mycoplasma infects detecting system
WO2017122816A1 (en) * 2016-01-15 2017-07-20 公益財団法人がん研究会 Novel fusion body and method for detecting same
CA3013366A1 (en) 2016-02-02 2017-08-10 Guardant Health, Inc. Cancer evolution detection and diagnostic
CN105842037B (en) * 2016-03-21 2018-07-31 山东农业大学 Colouring method that is a kind of while showing mast cell and acidophic cell
WO2017170803A1 (en) 2016-03-29 2017-10-05 株式会社国際電気通信基礎技術研究所 Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
US10370726B2 (en) 2016-04-14 2019-08-06 Mayo Foundation For Medical Education And Research Detecting colorectal neoplasia
CN105784873B (en) * 2016-05-06 2017-10-13 常熟市医学检验所 High lithemia injury of kidney early diagnosis marker and its application based on metabolism group
MX2018015184A (en) * 2016-06-07 2019-04-24 Univ Leland Stanford Junior Methods for diagnosis of bacterial and viral infections.
US11899020B2 (en) 2017-03-31 2024-02-13 The Regents Of The University Of California Shotgun proteomic antigen identification
CN107144620A (en) * 2017-03-31 2017-09-08 兰州百源基因技术有限公司 Diabetic nephropathy detects mark
CN107328746B (en) * 2017-06-14 2020-01-31 宁波大学 Preparation and application of multifunctional fluorescent biosensor based on nucleic acid-like coordination polymer
US20200141948A1 (en) * 2017-06-21 2020-05-07 Korea Research Institute Of Bioscience And Biotechnology Method and kit for diagnosis of muscle weakness-related diseases using blood biomarker
US11685951B2 (en) 2017-07-18 2023-06-27 The Research Foundation For The State University Of New York Biomarkers for intracranial aneurysm
CA3202766A1 (en) 2017-08-04 2019-02-07 Billiontoone, Inc. Sequencing output determination and analysis with target-associated molecules in quantification associated with biological targets
EP3665301B1 (en) * 2017-08-09 2023-10-04 PamGene B.V. Method for predicting the response of non-small-cell lung carcinoma patients to a medicament
BR112020010343A2 (en) 2017-11-23 2020-11-10 Biosearch, S.A. method to increase embryo implantation rate in a female patient suffering from polycystic ovary syndrome
CN109658980B (en) * 2018-03-20 2023-05-09 上海交通大学医学院附属瑞金医院 Screening and application of fecal gene markers
KR102072504B1 (en) * 2018-05-23 2020-02-03 중앙대학교 산학협력단 Composition and method for diagnosing atopic dermatitis using DOCK8 SNP
KR20210056955A (en) * 2018-06-01 2021-05-20 무스크 파운데이션 포 리서치 디벨롭먼트 Protein and cell glycan analysis
CN108841928B (en) * 2018-06-11 2021-11-23 河北医科大学 Human mitochondrial genome methylation detection kit and application thereof
WO2019241716A1 (en) * 2018-06-14 2019-12-19 Metabolomycs, Inc. Metabolomic signatures for predicting, diagnosing, and prognosing various diseases including cancer
CN108796067B (en) * 2018-07-03 2019-10-25 北京泱深生物信息技术有限公司 The diagnosis new function of MAEA gene in blood
CN109266734A (en) * 2018-09-25 2019-01-25 深圳市人民医院 Autoimmune disease diagnostic kit and application
CN109295230A (en) * 2018-10-24 2019-02-01 福建翊善生物科技有限公司 A method of the polygene combined abrupt climatic change based on ctDNA assesses tumour dynamic change
GB2612911B (en) 2019-02-14 2023-11-22 Mirvie Inc Methods and systems for determining a pregnancy-related state of a subject
EP3936624A4 (en) * 2019-03-08 2022-11-23 Neogentc Corp. Marker for predicting tumor reactivity of lymphocytes, and use thereof
CN109821029B (en) * 2019-04-08 2020-12-15 浙江大学 Application of ZDHHC21 gene in preparing leukemia induced differentiation therapeutic medicine
KR102169901B1 (en) * 2019-05-17 2020-10-26 연세대학교 산학협력단 Methods for providing information about responses to cancer immunotherapy using dna methylation and kits using the same
WO2020243589A1 (en) * 2019-05-29 2020-12-03 Washington University Methods of detecting clostridium difficile infections
WO2021041931A1 (en) * 2019-08-28 2021-03-04 The Regents Of The University Of California Methods of producing dna methylation profiles
CN110514847B (en) * 2019-09-24 2022-06-10 北京市心肺血管疾病研究所 Application of serum LysoPA in children dilated cardiomyopathy prognosis
CN112697889B (en) * 2019-10-22 2022-03-08 中国科学院大连化学物理研究所 Application of serum metabolism marker and detection kit
CN111189683A (en) * 2020-01-06 2020-05-22 中国科学院地质与地球物理研究所 Preparation method of ion probe liquid sample target
CN111341448B (en) * 2020-03-03 2023-12-19 西安交通大学 Method for predicting complex diseases and phenotype-associated metabolites based on Mendelian randomization
CN111041089B (en) * 2020-03-13 2020-06-19 广州微远基因科技有限公司 Application of host marker for COVID-19 infection
WO2021201111A1 (en) * 2020-04-01 2021-10-07 あすか製薬株式会社 Method for differentiating destructive thyroiditis from other pathological conditions
CN111334572B (en) * 2020-04-26 2020-10-27 江苏大学附属医院 New application of CTSZ gene methylation
CN112305220B (en) * 2020-06-03 2021-07-23 四川大学华西第二医院 Application of cathepsin Z in early warning and diagnosis of preeclampsia and product
CN111679018B (en) * 2020-08-14 2020-11-20 宝枫生物科技（北京）有限公司 Biomarkers for diagnosing cognitive disorders and uses thereof
CN112305118B (en) * 2020-10-30 2022-03-22 河北医科大学第二医院 L-octanoyl carnitine as biomarker for disease diagnosis
CN112501175A (en) * 2020-12-14 2021-03-16 南通大学 Psoriasis inhibiting gene and application thereof
US11152103B1 (en) 2020-12-29 2021-10-19 Kpn Innovations, Llc. Systems and methods for generating an alimentary plan for managing musculoskeletal system disorders
CN113295874B (en) * 2021-05-25 2022-03-04 广东源心再生医学有限公司 Novel marker for auxiliary diagnosis of valvular heart disease and auxiliary diagnosis product
CN113267394A (en) * 2021-06-10 2021-08-17 谱天（天津）生物科技有限公司 FFPE reference substance for proteome quality control, and preparation method and application thereof
CN113252910B (en) * 2021-06-29 2022-05-17 中国人民解放军军事科学院军事医学研究院 Application of TIMP3 in anxiety and depression diagnosis
CA3225337A1 (en) * 2021-07-09 2023-01-12 Brent WINSTON Metabolomic profiles for prediction of functional neurological outcome or death following severe traumatic brain injury
WO2023044118A1 (en) * 2021-09-20 2023-03-23 Droplet Biosciences, Inc. Methods for disease assessment using drain fluid
WO2023250229A1 (en) * 2022-06-23 2023-12-28 Oklahoma Medical Research Foundation Autoantibody biomarkers of ro/ss-a antibody negative sjogren's syndrome/sjogren's disease
CN115575646B (en) * 2022-11-21 2023-04-28 四川大学华西医院 Application of metabolic marker group in preparation of kit for predicting epileptic seizure

Family Cites Families (229)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
US5547835A (en) 1993-01-07 1996-08-20 Sequenom, Inc. DNA sequencing by mass spectrometry
US6172198B1 (en) 1993-03-19 2001-01-09 Northern Sydney Area Health Service PAPP-A, its immunodetection and uses
US5594637A (en) 1993-05-26 1997-01-14 Base Ten Systems, Inc. System and method for assessing medical risk
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US5514598A (en) 1993-11-30 1996-05-07 Doody; Michael Prenatal detection of meconium
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6031088A (en) 1996-05-23 2000-02-29 Albert Einstein College Of Medicine Of Yeshiva University Polycystic kidney disease PKD2 gene and uses thereof
GB9704444D0 (en) 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US20010051341A1 (en) 1997-03-04 2001-12-13 Isis Innovation Limited Non-invasive prenatal diagnosis
US20020119118A1 (en) 1997-11-03 2002-08-29 Genentech, Inc. Novel polypeptides and nucleic acids encoding bolekine
CA2359816C (en) 1999-01-06 2010-08-03 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
AU2005200170A1 (en) * 1999-03-05 2005-02-10 University Of Iowa Research Foundation Diagnostics and therapeutics for drusen associated ocular disorders
US6762032B1 (en) 1999-08-23 2004-07-13 Biocrystal, Ltd. Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response
EP1290227B1 (en) 2000-06-05 2009-08-12 Genetics Institute, LLC Compositions, kits, and methods for identification and modulation of type i diabetes
ES2291246T3 (en) 2000-06-27 2008-03-01 Von Recklinghausen Gesellschaft E.V. PROCEDURE FOR PURCHASING DATA FOR THE PRESINTOMATIC OR PRENATAL DIAGNOSIS OF NEUROPHRIBROMATOSIS OF TYPE 1.
US6664056B2 (en) 2000-10-17 2003-12-16 The Chinese University Of Hong Kong Non-invasive prenatal monitoring
FR2816411B1 (en) 2000-11-03 2003-07-04 Inst Nat Sante Rech Med MEANS FOR DETECTING THE PATHOLOGICAL TRANSFORMATION OF THE APP PROTEIN AND THEIR APPLICATIONS
US20030064380A1 (en) * 2001-01-29 2003-04-03 The Center For Blood Research, Inc. Anergy-regulated molecules
US6753137B2 (en) 2001-01-31 2004-06-22 The Chinese University Of Hong Kong Circulating epstein-barr virus DNA in the serum of patients with gastric carcinoma
GB0104690D0 (en) 2001-02-26 2001-04-11 Cytogenetic Dna Services Ltd Diagnostic test
FR2824144B1 (en) 2001-04-30 2004-09-17 Metagenex S A R L METHOD OF PRENATAL DIAGNOSIS ON FETAL CELLS ISOLATED FROM MATERNAL BLOOD
JP2004532633A (en) 2001-05-09 2004-10-28 ビオ・ビジョン・アーゲー Method for detecting progressive chronic dementia disease, peptide and detection reagent suitable therefor
WO2003019193A1 (en) 2001-08-30 2003-03-06 Ciphergen Biosystems, Inc. Method of diagnosing nephrotic syndrome
US6927028B2 (en) 2001-08-31 2005-08-09 Chinese University Of Hong Kong Non-invasive methods for detecting non-host DNA in a host using epigenetic differences between the host and non-host DNA
US20050130245A1 (en) 2001-09-17 2005-06-16 Syn X Pharma, Inc. Diagnosis and treatment of early pre-type-1 diabetes utilizing neuronal proteins
US7744876B2 (en) 2002-04-09 2010-06-29 The Curators Of The University Of Missouri Methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes
US7009038B2 (en) 2002-05-02 2006-03-07 Univ. Of Medicine & Dentistry Of N.J. pDJA1, a cardiac specific gene, corresponding proteins, and uses thereof
PT3072978T (en) 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 as a cardiovascular disease marker
US20040009518A1 (en) 2002-05-14 2004-01-15 The Chinese University Of Hong Kong Methods for evaluating a disease condition by nucleic acid detection and fractionation
US7157235B2 (en) 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
AU2003246380A1 (en) 2002-07-05 2004-01-23 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of tb2 gene and protein for neurodegenerative diseases
FR2844279A1 (en) 2002-09-06 2004-03-12 Inst Nat Sante Rech Med MEANS FOR DETECTING NEURODEGENERATIVE PROCESSES AND THEIR APPLICATIONS
JP2006511471A (en) 2002-09-16 2006-04-06 アブジェニックス インコーポレイテッド Method for treating nephritis using anti-PDGF-DD antibody
EP1571970B1 (en) 2002-10-02 2011-08-17 DMI Biosciences, Inc. Diagnosis and monitoring of diseases
US20040086864A1 (en) 2002-10-22 2004-05-06 The Chinese University Of Hong Kong Novel classification methods for pleural effusions
GB0225360D0 (en) 2002-10-31 2002-12-11 Univ London Genetic markers
AU2002952993A0 (en) 2002-11-29 2002-12-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Therapeutic and diagnostic agents
CN101245376A (en) 2003-01-17 2008-08-20 香港中文大学 Circulating mRNA as diagnostic markers for pregnancy-related disorders
WO2004070388A1 (en) 2003-02-04 2004-08-19 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases
WO2004071269A2 (en) 2003-02-13 2004-08-26 Intellectual Property Consulting Inc. Gene marker and composition for diagnosis and treatment of neurological disorders and diseases and use of the same
WO2004076639A2 (en) 2003-02-26 2004-09-10 Wyeth Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
EP1718327B1 (en) 2003-06-20 2015-01-07 University of Florida Biomarkers for differentiating between type 1 and type 2 diabetes
DE10333406A1 (en) 2003-07-15 2005-02-10 Protagen Ag T-regulatory cells containing galectins for the therapy and diagnosis of diseases
WO2005012907A1 (en) 2003-08-01 2005-02-10 Renovar, Inc. Systems and methods for characterizing kidney diseases
EP1664077B1 (en) 2003-09-05 2016-04-13 Trustees of Boston University Method for non-invasive prenatal diagnosis
US7445886B2 (en) 2003-09-10 2008-11-04 Board Of Regents, The University Of Texas System Macrophage migration inhibitory factor as a marker for cardiovascular risk
AU2004278782A1 (en) 2003-10-03 2005-04-14 Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Use of Cripto-1 as a biomarker for neurodegenerative disease and method of inhibiting progression thereof
EP1689884A4 (en) 2003-10-08 2007-04-04 Univ Boston Methods for prenatal diagnosis of chromosomal abnormalities
ATE435301T1 (en) 2003-10-16 2009-07-15 Sequenom Inc NON-INVASIVE DETECTION OF FETAL GENETIC CHARACTERISTICS
US20060094064A1 (en) 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
EP1685410A1 (en) 2003-11-19 2006-08-02 EVOTEC Neurosciences GmbH Diagnostic and therapeutic use of the human sgpl1 gene and protein for neurodegenerative diseases
EP1692520A2 (en) 2003-11-19 2006-08-23 Satoris, Inc. Method for diagnosis, stratification and monitoring of alzheimer's disease
WO2005072340A2 (en) 2004-01-27 2005-08-11 Compugen Ltd. Novel polynucleotides encoding polypeptides and methods using same
EP1711633A1 (en) 2004-02-04 2006-10-18 EVOTEC Neurosciences GmbH Diagnostic and therapeutic use of the kcne4 gene and protein for alzheimer disease
US20050266432A1 (en) 2004-02-26 2005-12-01 Illumina, Inc. Haplotype markers for diagnosing susceptibility to immunological conditions
US8071552B2 (en) 2004-04-05 2011-12-06 Universite Bordeaux 2 Peptides and peptidomimetics binding to CD23
US20080051334A1 (en) 2004-04-16 2008-02-28 Evotec Neurosciences Gmbh Diagnostic and Therapeutic Use of Kcnc1 for Neurodegenerative Diseases
EP2518510A1 (en) 2004-04-20 2012-10-31 SphingoTec GmbH Use of precursors of tachykinins and/or their fragments in medical diagnostic
AU2005240669A1 (en) 2004-05-07 2005-11-17 Garvan Institute Of Medical Research Detecting disease association with aberrant glycogen synthase kinase 3-beta expression
WO2005108999A2 (en) 2004-05-10 2005-11-17 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease
WO2005114222A1 (en) 2004-05-13 2005-12-01 Sphingo Tec Gmbh Use of precursors of enkephalins and/or their fragments in medical diagnostics
AU2005243064A1 (en) 2004-05-19 2005-11-24 Harold Wood Hospital ADAM12, a novel marker for abnormal cell function
US7709194B2 (en) 2004-06-04 2010-05-04 The Chinese University Of Hong Kong Marker for prenatal diagnosis and monitoring
CN101137903A (en) 2004-07-19 2008-03-05 罗彻斯特大学 Biomarkers of neurodegenerative disease
US20060024725A1 (en) 2004-07-30 2006-02-02 Robert Hussa Oncofetal fibronectin as a marker for pregnancy-related indications
WO2006020899A2 (en) 2004-08-13 2006-02-23 Metrigenix Corporation Markers for autoimmune disease detection
US20070087376A1 (en) 2004-08-30 2007-04-19 Potashkin Judith A Splice variants of pre-mRNA transcripts as biomarkers in idiopathic neurodegenerative diseases
US7595159B2 (en) 2004-11-03 2009-09-29 The Brigham And Women's Hospital, Inc. Prediction of Parkinson's disease using gene expression levels of peripheral blood samples
WO2006048778A1 (en) 2004-11-08 2006-05-11 King's College London Markers of predisposition to addictive states
US20060115855A1 (en) 2004-12-01 2006-06-01 Power3 Medical Products, Inc. FK506-binding protein 7 related protein as a biomarker for neurodegenerative disease
US20060115854A1 (en) 2004-12-01 2006-06-01 Power3 Medical Products, Inc. Acetyl-LDL receptor related proteins and peptides as a biomarker for neurodegenerative disease
WO2006061609A2 (en) 2004-12-07 2006-06-15 Electrophoretics Limited Diagnosis of neurodegenerative diseases
GB0426859D0 (en) 2004-12-07 2005-01-12 Proteome Sciences Plc Diagnosis of neurodegenerative disorders
AU2005323025A1 (en) 2004-12-31 2006-07-13 Biogen Idec Ma Inc. Polypeptides that bind BR3 and uses thereof
FR2880897B1 (en) 2005-01-18 2010-12-17 Inst Nat Sante Rech Med METHOD OF DETECTION, NON-INVASIVE, PRENATAL, IN VITRO OF NORMAL HEALTHY CONDITION, HEALTHY CARRIER STATUS OR SICK CARRIER STATUS OF MUCOVISCIDOSIS
US7432107B2 (en) 2005-01-24 2008-10-07 Roche Diagnostics Operations, Inc. Cardiac hormones for assessing cardiovascular risk
US7572592B2 (en) 2005-01-31 2009-08-11 Glycominds Ltd Method for diagnosing multiple sclerosis
US20070141625A1 (en) 2005-02-03 2007-06-21 Santos Jose H Method for assessing risk of and predisposition to development of a pathology related to the presence of anti-epcr autoantibodies
WO2006097049A1 (en) 2005-03-18 2006-09-21 The Chinese University Of Hong Kong A method for the detection of chromosomal aneuploidies
EP2612927B1 (en) 2005-03-18 2016-02-03 The Chinese University Of Hong Kong Markers for prenatal diagnosis and monitoring
CA2602963A1 (en) 2005-03-24 2006-09-28 Beth Israel Deaconess Medical Center Methods of diagnosing fetal trisomy 13 or a risk of fetal trisomy 13 during pregnancy
PT1866650E (en) 2005-04-06 2010-06-01 Univ Antwerp Neurodegenerative markers for depression.
WO2006111946A2 (en) 2005-04-18 2006-10-26 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Toll-like receptor 14 (tlr14 ) and use thereof
WO2006114661A1 (en) 2005-04-26 2006-11-02 Dwek Raymond A High throughput glycan analysis for diagnosing and monitoring rheumatoid arthritis and other autoimmune diseases
US8333970B2 (en) 2005-05-18 2012-12-18 Novartis Ag Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject having an inflammatory or autoimmune disease
GB0512401D0 (en) 2005-06-17 2005-07-27 Randox Lab Ltd Method
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
US20070148661A1 (en) 2005-07-19 2007-06-28 Duke University LSAMP Gene Associated With Cardiovascular Disease
US20070218469A1 (en) 2005-10-03 2007-09-20 Ruth Navon Novel mutations in hexosaminidase A
IL172297A (en) 2005-10-03 2016-03-31 Compugen Ltd Soluble vegfr-1 variants for diagnosis of preeclamsia
US20070218519A1 (en) 2005-10-11 2007-09-20 Tethys Bioscience, Inc. Diabetes-associated markers and methods of use thereof
US8652467B2 (en) 2005-10-14 2014-02-18 The Regents Of The University Of Michigan Dek protein compositions and methods of using the same
TW200726845A (en) 2006-01-02 2007-07-16 Nat Defense Medical Ct Biomarker molecular of renal illness and detecting method for the same
EP1808694A1 (en) 2006-01-17 2007-07-18 Universitätsklinikum Freiburg Method for diagnosing polycystic kidney disease
FR2896588B1 (en) 2006-01-20 2016-08-19 Univ D'angers METHOD OF IN VITRO DIAGNOSIS OF AUTOIMMUNE IMMUNE RESPONSE BY DETECTION OF ANTIBODIES AGAINST ANTIGEN PENTRAXIN 3.
EP1987361A4 (en) 2006-01-30 2009-03-04 Invitrogen Corp Compositions and methods for detecting and quantifying toxic substances in disease states
US7459280B2 (en) 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
EP2322531A3 (en) 2006-02-28 2011-09-07 Phenomenome Discoveries Inc. Methods for the diagnosis of dementia and other neurological disorders
US7488584B2 (en) 2006-03-24 2009-02-10 Picobella Methods for diagnosing and treating kidney and colorectal cancer
US20070224638A1 (en) 2006-03-27 2007-09-27 Institut Pasteur Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections
GB0606776D0 (en) 2006-04-03 2006-05-10 Novartis Pharma Ag Predictive biomarkers for chronic allograft nephropathy
EP1847615A1 (en) 2006-04-18 2007-10-24 Genoscreen Expression and polymorphism of the ornithine transcarbamylase (OTC) gene as markers for diagnosing Alzheimer's disease
US7662578B2 (en) 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
WO2007143295A2 (en) 2006-04-27 2007-12-13 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
DK2021796T3 (en) 2006-05-01 2012-05-29 Critical Care Diagnostics Inc Diagnosis of cardiovascular disease
US7901884B2 (en) 2006-05-03 2011-03-08 The Chinese University Of Hong Kong Markers for prenatal diagnosis and monitoring
US7754428B2 (en) 2006-05-03 2010-07-13 The Chinese University Of Hong Kong Fetal methylation markers
WO2007131345A1 (en) 2006-05-12 2007-11-22 The Hospital For Sick Children Genetic risk factor in sod1 and sfrs15 in renal disease, diabetic cataract, cardiovascular disease and longevity
WO2007132512A1 (en) 2006-05-12 2007-11-22 Keio University Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease
DK2548578T3 (en) 2006-05-17 2014-10-06 Ludwig Inst Cancer Res Targeting of VEGF-B regulation of fatty acid transporters for modulating human diseases
WO2007139895A2 (en) 2006-05-24 2007-12-06 Cellumen, Inc. Method for modeling a disease
US20080038269A1 (en) 2006-05-25 2008-02-14 Mount Sinai Hospital Methods for detecting and treating kidney disease
DE102006027818A1 (en) 2006-06-16 2007-12-20 B.R.A.H.M.S. Aktiengesellschaft In vitro multiparameter determination method for the diagnosis and early diagnosis of neurodegenerative diseases
WO2008084331A2 (en) 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
WO2008003826A1 (en) 2006-07-07 2008-01-10 Oy Jurilab Ltd Novel genes and markers in essential arterial hypertension
KR100856375B1 (en) 2006-07-18 2008-09-04 김현기 Marker for diagnosing Neurodegenerative diseases
US7851172B2 (en) 2006-07-25 2010-12-14 University Of Kentucky Research Foundation Biomarkers of mild cognitive impairment and alzheimer's disease
US20080026378A1 (en) 2006-07-28 2008-01-31 Gian Franco Bottazzo Prediction and prophylactic treatment of type 1 diabetes
US20080113358A1 (en) 2006-07-28 2008-05-15 Ravi Kapur Selection of cells using biomarkers
ITTO20060614A1 (en) 2006-08-21 2008-02-22 Uni Degli Studi Del Piemonte "DIFFERENTIAL DIAGNOSIS FOR THE SCLERODERMIA"
WO2008028257A1 (en) 2006-09-08 2008-03-13 Garvan Institute Of Medical Research Diagnostics and therapeutics of neurological disease
WO2008031917A1 (en) 2006-09-14 2008-03-20 Zora Biosciences Oy Biofluid metabolite profiling as a tool for early prediction of autoimmunity and type 1 diabetes risk
EP1905841A1 (en) 2006-09-25 2008-04-02 Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; Trex1 as a marker for lupus erythematosus
EP2067040A2 (en) 2006-09-26 2009-06-10 ProteoSys AG Use of at least one isoform of progesterone receptor membrane component 1 (pgrmc1)
US8110365B2 (en) 2006-10-05 2012-02-07 Rhode Island Hospital Compositions and methods for detecting and treating renal injury and inflammation
WO2008043725A1 (en) 2006-10-10 2008-04-17 Novartis Ag Biomarker in inflammatory disorders
WO2008043782A2 (en) 2006-10-11 2008-04-17 Novartis Ag Modulation of cd1b or cd1d expression in autoimmune disorders
WO2008046512A1 (en) 2006-10-16 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Prss23 as a biomarker, therapeutic and diagnostic target
WO2008046510A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Fn1 as a biomarker, therapeutic and diagnostic target
EP2102357B1 (en) 2006-10-16 2013-11-27 Bayer Intellectual Property GmbH Ltbp2 as a biomarker, therapeutic and diagnostic target
EP2118135A1 (en) 2006-10-16 2009-11-18 Bayer Schering Pharma AG Crtac as a biomarker, therapeutic and diagnostic target
WO2008046160A1 (en) 2006-10-20 2008-04-24 Newcastle Innovation Limited Assay for the detection of biomarkers associated with pregnancy related conditions
WO2008063369A2 (en) 2006-11-01 2008-05-29 George Mason Intellectual Properties, Inc. Biomarkers for neurological conditions
EP2089712A4 (en) 2006-11-22 2010-09-22 Life Technologies Corp Autoimmune disease biomarkers
WO2008068024A2 (en) 2006-12-06 2008-06-12 Universität Zürich Means and methods for isolating and determining novel targets for the treatment of neurodegenerative, neurological or neuropsychiatric disorders and compositions comprising the same
IL180095A0 (en) 2006-12-14 2007-05-15 Ohad Birk Method for antenatal estimation of down syndrome risk
US8362224B2 (en) 2006-12-19 2013-01-29 The Trustees Of The University Of Pennsylvania Screening for CD93 (C1qRp)-associated polymorphism(S) in the diagnosis, prevention and treatment of autoimmune diseases
US8815519B2 (en) 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
CA2689296C (en) 2007-01-10 2015-11-17 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
WO2008085024A1 (en) 2007-01-12 2008-07-17 Erasmus University Medical Center Rotterdam Identification and detection of peptides relating to specific disorders
EP2468888B1 (en) 2007-01-22 2018-04-11 Medizinische Universität Innsbruck Novel markers for chronic kidney disease
JP2010517540A (en) 2007-02-08 2010-05-27 ポウムリ リミテッド Diagnosis of neurodegenerative diseases
WO2008100596A2 (en) 2007-02-15 2008-08-21 Burnham Institute For Medical Research Biomarkers of neurodegenerative disease
AU2008218542B2 (en) 2007-02-21 2014-06-26 Decode Genetics Ehf. Genetic susceptibility variants associated with cardiovascular disease
US20080227709A1 (en) 2007-03-14 2008-09-18 Baylor Research Institute Gene expression in peripheral blood mononuclear cells from children with diabetes
EP2134744A2 (en) 2007-03-26 2009-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Schizophrenia-related isoform of kcnh2 and development of antipsychotic drugs
EP1975252A1 (en) 2007-03-29 2008-10-01 INSERM (Institut National de la Santé et de la Recherche Medicale) Methods for the prognosis or for the diagnosis of a thyroid disease
US20120052592A9 (en) 2007-03-30 2012-03-01 Nano Solution, Inc., Method for determining prognosis of acute central nervous system disorder
JP2010523629A (en) 2007-04-12 2010-07-15 アピトープ インターナショナル エヌフェー Biomarkers for multiple sclerosis
GB0707933D0 (en) 2007-04-24 2007-05-30 Apitope Technology Bristol Ltd Disease markers
GB0708075D0 (en) 2007-04-26 2007-06-06 Univ Nottingham Nethods
AU2008247649A1 (en) 2007-05-01 2008-11-13 University Of Miami Transcriptomic biomarkers for individual risk assessment in new onset heart failure
WO2008137838A2 (en) 2007-05-03 2008-11-13 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
WO2008147938A2 (en) 2007-05-24 2008-12-04 Centocor, Inc. Wnt5a as an inflammatory disease marker
EP2160478B1 (en) 2007-06-06 2014-08-27 Siemens Healthcare Diagnostics Inc. Predictive diagnostics for kidney disease
US20090142792A1 (en) 2007-06-21 2009-06-04 Robinson William H Biomarkers for the diagnosis of autoimmune disease
ITRM20070351A1 (en) 2007-06-22 2008-12-23 Istituto Naz Per Le Malattie I GENE CODIFYING AMBER PROTEIN 1 HAVING REGULATORY ACTIVITY OF THE SELF-FAILURE AND DEVELOPMENT OF THE CENTRAL NERVOUS SYSTEM
WO2009000520A1 (en) 2007-06-25 2008-12-31 Universität Duisburg-Essen Screening-method for polymorphic markers in htra1 gene in neurodegenerative disorders
EP2167961A4 (en) 2007-06-27 2010-07-21 Univ Leland Stanford Junior Beta2-microglobulin and c reactive protein (crp) as biomarkers for peripheral artery disease
FR2918329B1 (en) 2007-07-06 2009-10-02 Renault Sas COOLING ECOPE FOR MOTOR VEHICLE
WO2009012156A2 (en) 2007-07-13 2009-01-22 Genentech, Inc. Treatments and diagnostics for cancer, inflammatory disorders and autoimmune disorders
MX341954B (en) 2007-07-17 2016-09-08 Metabolon Inc Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same.
KR20100063052A (en) 2007-08-02 2010-06-10 아이에스에스 이뮨 시스템 스티뮬레이션 에이비 Diagnosis, staging and monitoring of inflammatory bowel disease
US9086425B2 (en) 2007-08-29 2015-07-21 The Cleveland Clinic Foundation Carbamylated proteins and risk of cardiovascular disease
US20090275046A1 (en) 2007-08-29 2009-11-05 Power3 Medical Products, Inc. Complement factor H protein as a biomarker of Parkinson's disease
US8748100B2 (en) 2007-08-30 2014-06-10 The Chinese University Of Hong Kong Methods and kits for selectively amplifying, detecting or quantifying target DNA with specific end sequences
GB0717637D0 (en) 2007-09-10 2007-10-17 Univ Leiden Future cardiac event biomarkers
ITUD20070183A1 (en) 2007-10-01 2009-04-02 Univ Degli Studi Udine DIAGNOSTIC AND PROGNOSTIC METHOD FOR DIAGNOSIS AND PROGNOSIS OF LYMPHOPROLIFERATION IN AUTOIMMUNE DISEASES
US8062852B2 (en) 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
GB0720113D0 (en) * 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
CA2703165A1 (en) 2007-10-22 2009-04-30 The Regents Of The University Of California Biomarkers for prenatal diagnosis of congenital cytomegalovirus
FI20070795A0 (en) 2007-10-24 2007-10-24 Faron Pharmaceuticals Oy A new biomarker for monitoring disease development and assessing the effectiveness of therapies
EP2203745A4 (en) 2007-10-26 2010-12-08 Biohit Oyj Methods and products for diagnosing autoimmune diseases and gastric cancer linked with atrophic gastritis
WO2009059259A2 (en) 2007-10-31 2009-05-07 Children's Hospital Medical Center Detection of worsening renal disease in subjects with systemic lupus erythematosus
WO2009058168A1 (en) 2007-11-04 2009-05-07 Prediction Sciences Llc Cellular fibronectin as a diagnostic marker in cardiovascular disease and methods of use thereof
ES2379673T3 (en) 2007-11-08 2012-04-30 Novartis Ag Gene expression signatures for chronic / sclerosing aloingert nephropathy
US8008013B2 (en) 2007-11-16 2011-08-30 Oklahoma Medical Research Foundation Predicting and diagnosing patients with autoimmune disease
EP2245188A2 (en) 2007-11-28 2010-11-03 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Biomarkers for the onset of neurodegenerative diseases
US8506933B2 (en) 2007-11-30 2013-08-13 Msdx, Inc. Methods of detecting a neurological condition via analysis of circulating phagocytes
WO2009074331A2 (en) 2007-12-11 2009-06-18 Julius-Maximilians-Universität Würzburg Early and differential diagnosis test for alzheimer's disease
WO2009075566A1 (en) 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
EP2075343A1 (en) 2007-12-21 2009-07-01 Gert Mayer A method of diagnosing a progressive disease
WO2009083950A2 (en) 2007-12-27 2009-07-09 Compugen Ltd. Biomarkers for the prediction of renal injury
SG10201704689XA (en) * 2008-01-18 2017-07-28 Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
KR20100128281A (en) 2008-01-23 2010-12-07 릭스하스피탈렛 Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40
WO2009097450A1 (en) 2008-01-30 2009-08-06 Dexcom. Inc. Continuous cardiac marker sensor system
JP2011511301A (en) 2008-02-04 2011-04-07 バンヤン・バイオマーカーズ・インコーポレイテッド Methods for diagnosing or treating brain injury
JP2011511804A (en) 2008-02-08 2011-04-14 メディミューン，エルエルシー Disease markers and uses thereof
US20090239242A1 (en) 2008-03-18 2009-09-24 Biotrin Intellectual Properties Limited Method for the early identification and prediction of kidney injury
CA2646040A1 (en) 2008-03-22 2009-09-22 David V. Pow Detection of a biomarker of aberrant cells of neuroectodermal origin in a body fluid
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
EP2107377A1 (en) 2008-04-04 2009-10-07 BRAHMS Aktiengesellschaft Pro-endothelin-1 levels for the prediction of risk of tachyarrhytmic events
WO2009122387A1 (en) 2008-04-04 2009-10-08 Biotrin Group Ltd. Method for the detection and prediction of obesity-related renal disease
EP2279270B1 (en) 2008-04-15 2014-06-18 Oberbauer, Rainer Markers of acute kidney failure
US8030097B2 (en) 2008-04-30 2011-10-04 Versitech Limited and R & C Biogenius Limited Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
WO2010005750A2 (en) 2008-06-16 2010-01-14 The Regents Of The University Of California Potential prognostic markers and therapeutic targets for neurological disorders
US20100167937A1 (en) 2008-07-08 2010-07-01 Power3 Medical Products, Inc. Multiple forms of Alzheimer's disease based on differences in concentrations of protein biomarkers in blood serum
US20110177509A1 (en) 2008-07-23 2011-07-21 The Washington University Risk factors and a therapeutic target for neurodegenerative disorders
JP2011529453A (en) 2008-07-31 2011-12-08 ホスピタル クリニク アイ プロビンシアル デ バルセロナ Healthy kidney biomarkers
WO2010019553A2 (en) 2008-08-11 2010-02-18 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
ES2341419B1 (en) 2008-08-14 2011-05-03 Hospital Clinic I Provincial De Barcelona WNT1 AS RENAL DAMAGE BIOMARCATOR.
WO2010022210A2 (en) 2008-08-21 2010-02-25 Pxbiosciences Llc Diagnosis and monitoring of renal failure using peptide biomarkers
WO2010025434A1 (en) 2008-08-29 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2161577A1 (en) * 2008-09-01 2010-03-10 Atlas Antibodies AB ANLN protein
CN102224421A (en) 2008-09-30 2011-10-19 弗·哈夫曼-拉罗切有限公司 Biological markers predictive of rheumatoid arthritis response to lymphotoxin antagonists
US20100124756A1 (en) 2008-10-10 2010-05-20 Sandip Ray Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids
GB0818650D0 (en) 2008-10-10 2008-11-19 Uni I Oslo Methods
EP2767833A3 (en) 2008-10-21 2014-12-17 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN103760359B (en) 2008-10-21 2017-01-11 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2180322A1 (en) 2008-10-22 2010-04-28 BRAHMS Aktiengesellschaft Prognostic biomarkers for the progression of primary chronic kidney disease
KR101051435B1 (en) * 2008-10-22 2011-07-22 한국생명공학연구원 Colorectal cancer diagnostic kit using colorectal cancer-related markers and colorectal cancer diagnostic method using the same
WO2010048497A1 (en) 2008-10-24 2010-04-29 Genizon Biosciences Inc. Genetic profile of the markers associated with alzheimer's disease
WO2010046503A2 (en) 2008-10-24 2010-04-29 Vereniging Vu-Windesheim Biomarkers for predicting the development of chronic autoimmune diseases
US20110236397A1 (en) 2008-11-06 2011-09-29 University Of Miami Limited proteolysis of cd2ap and progression of renal disease
GB2477439B (en) 2008-11-07 2012-02-15 Sequenta Inc Methods for correlating clonotypes with a disease in a patient
CN102264230B (en) 2008-11-10 2014-12-10 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102209894A (en) 2008-11-11 2011-10-05 安特鲁斯公司 Biomarkers for assessing atherosclerotic potential
US20120094295A1 (en) 2008-11-21 2012-04-19 The Johns Hopkins University Neurodegenerative disease diagnostic compositions and methods of use
BRPI0921921A2 (en) 2008-11-22 2019-09-24 Astute Medical Inc method for assessing renal condition in an individual; and, use of one or more markers of renal injury.
IT1392551B1 (en) 2008-11-25 2012-03-09 Bioindustry Park Del Canavese S P A BIOMARCERS FOR DIAGNOSIS AND TO DETECT THE PROGRESSION OF NEURODEGENERATIVE DISEASES, IN PARTICULAR OF AMIOTROPHIC LATERAL SCLEROSIS
US20120094315A1 (en) 2008-12-09 2012-04-19 Stephanie Fryar-Williams Biomarkers for the diagnosis and/or prediction of susceptibility to mental and neurodegenerative disorders
WO2010068686A2 (en) 2008-12-10 2010-06-17 Joslin Diabetes Center, Inc. Methods of diagnosing and predicting renal disease

Also Published As

Publication number Publication date
BR112013001754A2 (en) 2016-05-31
AU2011280996B2 (en) 2017-03-30
EP2596132A2 (en) 2013-05-29
MX361944B (en) 2018-12-19
AU2017201440B2 (en) 2019-06-20
EP4303584A3 (en) 2024-04-03
EP2596132A4 (en) 2013-12-18
KR20130041961A (en) 2013-04-25
CN103119179A (en) 2013-05-22
JP2021074011A (en) 2021-05-20
CN110846405A (en) 2020-02-28
JP2017060479A (en) 2017-03-30
US20220298582A1 (en) 2022-09-22
US20190085402A1 (en) 2019-03-21
US20150299810A1 (en) 2015-10-22
US20220298583A1 (en) 2022-09-22
CA2806291A1 (en) 2012-01-26
AU2011280996A1 (en) 2013-02-28
JP2023101574A (en) 2023-07-21
CA2806291C (en) 2023-08-29
US20120053073A1 (en) 2012-03-01
EP4303584A2 (en) 2024-01-10
MX2013000916A (en) 2013-07-05
WO2012012693A2 (en) 2012-01-26
EA201390150A1 (en) 2013-09-30
SG187159A1 (en) 2013-02-28
JP2013538565A (en) 2013-10-17
AU2017201440A1 (en) 2017-03-16
JP2019068804A (en) 2019-05-09
WO2012012693A3 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
IL257739A (en) Methods for detecting signatures of disease or conditions in bodily fluids
SG10201505723UA (en) Methods for detecting signatures of disease or conditions in bodily fluids
ZA201300723B (en) Non-reusable collection device for bodily fluids
ZA201300435B (en) Apparatus for disease detection
ZA201401183B (en) Fluid level sensor and related methods
HK1200037A1 (en) Non-invasive methods of detecting target molecules
EP2539019A4 (en) Concurrent stimulation effect detection
EP4108782C0 (en) Compositions and methods for analyte detection
EP2585833A4 (en) Methods for detecting cancer
IL226846B (en) Micro-devices for disease detection
EP2596117A4 (en) Methods of detecting kidney-associated diseases or conditions
HK1204016A1 (en) Methods and kits for detecting subjects at risk of having cancer
HK1185245A1 (en) Improved system for detecting symptoms of hypoglycemia
GB201004923D0 (en) Compact method for medical detection
EP2693953A4 (en) Multi-modality medical sensing system and method
ZA201404463B (en) Detecting analytes
EP2721404A4 (en) Diagnosis and prognosis of renal injury and renal failure
ZA201401830B (en) Dynamic surgical fluid sensing
AP2014007563A0 (en) Biosensor for point-of-care diagnostic and on-sitemeasurements
EP2786150A4 (en) Detection of multiple analytes
EP2451966A4 (en) Methods for early detection of blood disorders
EP2614160A4 (en) Detection of rna-interacting regions in dna
GB0921712D0 (en) Methods of detecting DNA damage
EP2578699A4 (en) Methods for detection of risk of obesity and risk of onset of diabetes
EP2559970A4 (en) Displacement sensor and method for detecting displacement